NUP98r acute leukemia, post-transplant maintenance¶

Abstract: 6505 · Session: Oral presentation (Hematologic Malignancies—Leukemia), Tuesday, Jun 2, 2026, 9:45 am–12:45 pm CT · Presenter: not yet disclosed (Syndax/investigators) · Embargo: through presentation, Jun 2, 2026

At a glance¶

Sponsor: Syndax Pharmaceuticals
PI / presenter: Not yet disclosed in pre-meeting release
NCT ID: Not specified in announcement (Syndax revumenib post-HSCT maintenance program; related post-transplant study NCT06575296)
Phase: Investigator/early-phase maintenance experience (observational + historical-control comparison)
Design: Revumenib as maintenance therapy following allogeneic hematopoietic stem cell transplantation (allo-HSCT), with comparison to a historical cohort of the same genetic subtypes treated before revumenib
N: 21 adults and children
Primary endpoint(s): Overall survival; relapse rate
Comparator: Historical cohort (same genetic subtypes, pre-revumenib era)
Indication: KMT2A-rearranged (KMT2Ar), NPM1-mutant (NPM1m), or NUP98-rearranged (NUP98r) acute leukemia
Line: Post-allo-HSCT maintenance

Headline result¶

Syndax reported in its pre-meeting announcement that the oral presentation will describe favorable overall survival and relapse outcomes among 21 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who received revumenib as post-transplant maintenance, benchmarked against a historical cohort of the same genetic subtypes treated before revumenib became available. Specific OS, relapse-rate, HR, and p-value figures were not released pre-meeting and are embargoed until the Jun 2, 2026 presentation (per Syndax topline, May 21, 2026).

Mechanism / class¶

Revumenib (Revuforj) is an oral, first-in-class menin inhibitor that disrupts the menin–KMT2A protein interaction driving leukemic transcriptional programs in KMT2A-rearranged and NPM1-mutant leukemias. FDA-approved for relapsed/refractory acute leukemia with a KMT2A translocation (adult and pediatric ≥1 year) and for relapsed/refractory AML with a susceptible NPM1 mutation (adult and pediatric ≥1 year with no satisfactory alternative).

Discussant takeaway¶

Not reported pre-meeting; omit pending presentation.

Practice-changing?¶

Pending. Post-transplant maintenance is a genuine unmet need in menin-dependent acute leukemias, but this is a small (N=21), historically-controlled experience rather than a randomized trial. Hypothesis-generating; the randomized phase 3 newly-diagnosed programs (EVOLVE-2, REVEAL-ND) will drive any practice change.

Cross-links¶

Other ASCO 2026 revumenib abstracts (Syndax): Abstract 6528 — revumenib pharmacokinetics in R/R acute leukemias (poster, Mon Jun 1); TPS6600 — EVOLVE-2 phase 3 revumenib + venetoclax/azacitidine in newly diagnosed NPM1m/KMT2Ar AML ineligible for intensive chemo (trial-in-progress poster, Mon Jun 1); TPS6602 — REVEAL-ND phase 3 revumenib + intensive chemotherapy in newly diagnosed NPM1m AML (trial-in-progress poster, Mon Jun 1)
AACR 2026: ../../aacr-2026/index.md
JPM 2026: ../../jpm-2026/index.md

Sources¶

Syndax press release (GlobeNewswire), May 21, 2026: https://www.globenewswire.com/news-release/2026/05/21/3299789/0/en/Syndax-Announces-Four-Revuforj-revumenib-Abstracts-Accepted-for-ASCO-2026-Including-an-Oral-Presentation-of-Post-Transplant-Data.html
Syndax IR: https://ir.syndax.com/news-releases/news-release-details/syndax-announces-four-revuforjr-revumenib-abstracts-accepted
StockTitan coverage: https://www.stocktitan.net/news/SNDX/syndax-announces-four-revuforj-revumenib-abstracts-accepted-for-asco-jeix3rcpgnnh.html
Related post-HSCT study (ClinicalTrials.gov): https://clinicaltrials.gov/study/NCT06575296
Background — AUGMENT-101 (JCO): https://ascopubs.org/doi/10.1200/JCO.24.00826